Immunomodulatory Effects of Bacterial Lysates Combined with Bronchoalveolar Lavage on Cytokine Regulation and T-cell Responses in Pseudomonas aeruginosa–colonized Bronchiectasis
Abstract
Natural killer (NK) cells contribute to the development of Rheumatoid Arthritis (RA). Increased expression of programmed cell death protein 1 (PD-1), encoded by the PDCD1 gene, indicates NK cell exhaustion, a process that may be influenced by microRNAs (miRNAs). In this study, we examined PD-1 expression on NK cells from RA patients and evaluated whether miRNAs modulate this pathway.
Although antibiotics are critical for treating infections, they can provoke harmful immune responses by releasing bacterial components that overstimulate the immune system. Such responses may lead to excessive inflammation or cytokine storms. To address this risk, we assessed the immune safety of a newly designed chimeric endolysin, ZAM-MSC, and compared its effects with traditional antibiotics using transcriptomic, proteomic, and computational analyses.
We analyzed public gene and protein expression datasets from antibiotic-treated human cells and performed in silico studies on ZAM-MSC. Differential expression analysis and pathway enrichment were conducted, alongside structural modeling of the endolysin and its predicted interactions with immune receptors.
Antibiotic treatment strongly activated inflammatory genes and pathways, including nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK). In contrast, ZAM-MSC minimally affected immune-related gene expression, with downregulation of interleukin-6 receptor (IL6R) and tumor necrosis factor receptor 1A (TNFRSF1A). Structural modeling showed weak interactions with Toll-like receptors, and epitope analysis predicted low immunogenicity. These results suggest ZAM-MSC may offer a safer antimicrobial alternative, though all protein-level findings are based on computational predictions and require experimental validation.
2. Chalmers JD, Chang AB, Chotirmall SH, Dhar R, Mcshane PJ. Bronchiectasis. Nat Rev Dis Primers. 2018;4(1):45.
3. Zhu D, Huang MF, Xu A, Gao X, Huang YW, Phan T, et al. Systematic transcriptome profiling of hPSC-derived osteoblasts unveils CORIN's mastery in governing osteogenesis through CEBPD modulation. J Biol Chem. 2024;300(8):107494.
4. Vidaillac C, Chotirmall SH. Pseudomonas aeruginosa in bronchiectasis: infection, inflammation, and therapies. Expert Rev Respir Med. 2021;15(5):649-62.
5. Wang R, Ding S, Lei C, Yang D, Luo H. The contribution of pseudomonas aeruginosa infection to clinical outcomes in bronchiectasis: a prospective cohort study. Ann Med. 2021;53(1):459-69.
6. Liu Y, Du L, Zhu Y, Liu X, Zhou N, Li C, et al. A truncated mutation of MucA in pseudomonas aeruginosa from a bronchiectasis patient affects t3SS expression and inflammasome activation. Acta Biochim Biophys Sin (Shanghai). 2022;54(11):1740-47.
7. Hilliam Y, Moore MP, Lamont IL, Bilton D, Haworth CS, Foweraker J, et al. Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung. Eur Respir J. 2017;49(4).
8. [Expert consensus on the diagnosis and treatment of adult bronchiectasis in china]. Zhonghua Jie He He Hu Xi Za Zhi. 2021;44(4):311-21.
9. Liu Y, Lu HW, Gu SY, Wang WW, Ge J, Jie ZJ, et al. Bronchoscopic airway clearance therapy for acute exacerbations of bronchiectasis. EBioMedicine. 2021;72:103587.
10. Suarez N, Ferrara F, Rial A, Dee V, Chabalgoity JA. Bacterial lysates as immunotherapies for respiratory infections: methods of preparation. Front Bioeng Biotechnol. 2020;8:545.
11. Zhu LL, Wang YH, Feng JH, Zhou Q. Oral bacterial lysate OM-85: advances in pharmacology and therapeutics. Drug Des Devel Ther. 2024;18:4387-4399.
12. Esposito S, Bianchini S, Bosis S, Tagliabue C, Coro I, Argentiero A, et al. A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections. J Transl Med. 2019;17(1):284.
13. Xie C, Wen Y, Zhao Y, Zeng S, Guo Q, Liang Q, et al. Clinical features of patients with bronchiectasis with comorbid chronic obstructive pulmonary disease in china. Med Sci Monit. 2019;25:6805-11.
14. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase i. RhDNase study group. Chest. 1998;113(5):1329-34.
15. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1975;67(3):215-6.
16. Metersky ML, Barker AF. The pathogenesis of bronchiectasis. Clin Chest Med. 2022;43(1):35-46.
17. Mcshane PJ, Tino G. Bronchiectasis. Chest. 2019;155(4):825-33.
18. Swenson C, Schraufnagel D, Sadikot R. What is bronchiectasis? Am J Respir Crit Care Med. 2017;195(8):P15-6.
19. Radovanovic D, Santus P, Blasi F, Sotgiu G, D'Arcangelo F, Simonetta E, et al. A comprehensive approach to lung function in bronchiectasis. Respir Med. 2018;145:120-9.
20. Martinez-Garcia MA, Oscullo G, Posadas T, Zaldivar E, Villa C, Dobarganes Y, et al. Pseudomonas aeruginosa and lung function decline in patients with bronchiectasis. Clin Microbiol Infect. 2021;27(3):428-34.
21. King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2009;4:411-9.
22. Barker AF. Bronchiectasis. N Engl J Med. 2002;346(18):1383-93.
23. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45(5):1446-62.
24. Frija-Masson J, Martin C, Regard L, Lothe MN, Touqui L, Durand A, et al. Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis. Eur Respir J. 2017;49(4).
25. Yavasoglu I. CD4+CD8+ double-positive t-lymphocytes: pitfalls. Turk J Haematol. 2020;37(3):216-7.
26. Zander R, Schauder D, Xin G, Nguyen C, Wu X, Zajac A, et al. CD4(+) t cell help is required for the formation of a cytolytic CD8(+) t cell subset that protects against chronic infection and cancer. Immunity. 2019;51(6):1028-1042.e4.
27. Alcaraz-Serrano V, Fernandez-Barat L, Scioscia G, Llorens-Llacuna J, Gimeno-Santos E, Herrero-Cortina B, et al. Mucoid pseudomonas aeruginosa alters sputum viscoelasticity in patients with non-cystic fibrosis bronchiectasis. Respir Med. 2019;154:40-6.
28. Chai YH, Xu JF. How does pseudomonas aeruginosa affect the progression of bronchiectasis? Clin Microbiol Infect. 2020;26(3):313-8.
29. Jurkiewicz D, Zielnik-Jurkiewicz B. Bacterial lysates in the prevention of respiratory tract infections. Otolaryngol Pol. 2018;72(5):1-8.
30. Chalmers JD, Cipolla D, Thompson B, Davis AM, O'Donnell A, Tino G, et al. Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies. Eur Respir J. 2020;56(4).
31. Xu YD, Cheng M, Shang PP, Yang YQ. Role of IL-6 in dendritic cell functions. J Leukoc Biol. 2022;111(3):695-709.
32. Lin HC, Hsieh MH, Lo YL, Huang HY, Huang SW, Huang CD, et al. IL-6 and TIMP-1 correlated to airway pathogen colonization and predict disease severity in patients with non-cystic fibrosis bronchiectasis. J Inflamm Res. 2024;17:5701-9.
33. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory t cells. Nature. 2006;441(7090):235-8.
34. Parola C, Salogni L, Vaira X, Scutera S, Somma P, Salvi V, et al. Selective activation of human dendritic cells by OM-85 through a NF-kb and MAPK dependent pathway. PLoS One. 2013;8(12):e82867.
| Files | ||
| Issue | Articles in Press | |
| Section | Original Article(s) | |
| Keywords | ||
| Antibiotic alternatives Chimeric endolysin Cytokine release syndrome Immune safety Immunoinformatics NF-κB | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |

